EUR 5.25: bonyf (MLBON.PA) EURONEXT closed 03 Feb 2026: watch EUR 8.00 bounce

MLBON.PA stock closed at EUR 5.25 on 03 Feb 2026 on EURONEXT, leaving the share near its short-term support after heavy declines. Trading volume was negligible at 6 shares, which magnifies short-term moves. Technicals point to an extreme oversold profile that can trigger a bounce. We outline the technical trigger, valuation context, Meyka AI grade, and a practical oversold bounce trade plan for investors watching bonyf N.V. (MLBON.PA) in the Belgium healthcare segment.

MLBON.PA stock: Price snapshot and session close

bonyf (MLBON.PA) finished the session at EUR 5.25 on EURONEXT with volume 6 and previous close EUR 5.25. The share sits above its 52-week low of EUR 3.96 and well below the 50-day average of EUR 8.21 and 200-day average of EUR 12.35. Market cap is EUR 3,090,150 and shares outstanding are 588,600.

MLBON.PA stock: Technicals show an oversold bounce setup

Technicals show an extremely low RSI reading of 0.00 and an ADX of 100.00, signalling a strong trend but an oversold extreme. MACD is negative (MACD -0.32, signal -0.15). Keltner channels place recent price near the lower band at EUR 5.35. These readings create a high-probability short-term mean reversion trade if volume picks up above the avgVolume 8 benchmark.

MLBON.PA stock: Fundamentals and valuation context

bonyf operates in Healthcare, Medical – Instruments & Supplies, and reports EPS -1.77 with a reported PE of -2.97. Price to book is 1.17 and price to sales is 10.98. Free cash flow yield is strong at 18.43%, yet current ratio is 0.51, indicating tight liquidity. The company’s sector average PE is 34.32, highlighting valuation divergence versus larger peers.

Meyka AI rates MLBON.PA with a score out of 100 and forecast

Meyka AI rates MLBON.PA with a score of 61.21 out of 100 (Grade B, Suggestion: HOLD). This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst sentiment. Meyka AI’s forecast model projects monthly EUR 5.50, quarterly EUR 2.23, and yearly EUR 4.87. These model-based projections imply a yearly change of -7.18% versus the current price of EUR 5.25. Forecasts are model-based projections and not guarantees.

MLBON.PA stock: Catalysts, risks and sector context

Catalysts include improved trading liquidity, any product updates from bonyf, or distribution deals for PerioTabs and denture products. Risks include low liquidity, thin trading (volume 6) and negative margins with net income pressure. The Healthcare sector in Europe shows average PE 34.32, so MLBON.PA’s negative earnings and low current ratio raise relative risk versus peers.

MLBON.PA stock: Practical oversold bounce trade plan

For an oversold bounce strategy, consider a scaled entry near EUR 5.00–5.50 with a stop below EUR 4.75 and a short-term target at the 50-day average near EUR 8.00. A medium-term target aligned with the 200-day mean is EUR 12.35. Position sizing should account for very low liquidity and wide implied move risk. Track volume above 8 shares to confirm buy-side interest.

Final Thoughts

Key takeaways for MLBON.PA stock: the share closed EUR 5.25 on 03 Feb 2026 with minimal volume, producing a textbook oversold technical setup. Meyka AI’s model projects yearly EUR 4.87, implying -7.18% versus today, while a short-term oversold bounce target at EUR 8.00 implies +52.38% upside. Our Meyka AI grade is 61.21 (B, HOLD), which blends relative sector weakness with pockets of value such as a 18.43% free cash flow yield. Traders seeking an oversold bounce should prioritise liquidity confirmation and tight risk controls. Forecasts are model-based projections and not guarantees. For company detail and filings visit the official site source and the Euronext listing source. Meyka AI provided the above analysis as an AI-powered market analysis platform and does not offer financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.